| INN or code Name |
Company |
Targets |
Type |
Conditions |
Clinical
status |
|
RO5520985 |
Roche |
Ang2 x VEGF |
CrossMAb |
Solid tumors |
phase 1 |
|
AMG212 |
Bayer |
PSMA x CD3 |
BiTE |
ProstaticNeoplasms |
phase 1 |
|
MT110 |
Amgen |
EpCAM x CD3 |
BiTE |
Solid Tumors |
phase 1 |
|
MT111 |
Amgen |
CEA x CD3 |
BiTE |
MetastaticBreast Cancer |
phase 1 |
|
IMCgp100 |
Immunocore |
gp100 x CD3 |
ImmTAC |
MalignantMelanoma |
phase 1 |
|
IMP-288 |
Immunomedics |
CEA x hapten |
IgG1 |
HER2 NegativeBreastCarcinoma |
phase 1 |
|
ABT-165 |
AbbVie |
Undisclosed |
DVD-Ig |
Solid Tumors |
phase 1 |
|
ABT-981 |
AbbVie |
IL-1α x IL-1β |
DVD-Ig |
Osteoarthritis |
phase 1 |
|
ACE910 |
Chugai |
Factor Xa x factor X |
IgG |
Hemophilia |
phase 1 |
|
AFM11 |
Affimed |
CD19 x CD3 |
TandAb |
NonHodgkin'slymphoma |
phase 1 |
|
MGD006 |
Macrogenics |
CD123 x CD3 |
DART |
Acute myelogenousleukemia |
phase 1 |
| COVA322 |
Covagen |
TNFa x IL17 |
FynomAb |
RheumatoidArthritis / PsoriaticArthritis |
phase 1 |
|
AFM13 |
Affimed |
CD30 x CD16 |
TandAb |
Hodgkin'slymphoma |
phase 2 |
|
FBTA05 |
Fresenius, Trion |
CD20 x CD3 |
Triomab |
B celllymphoma |
phase 2 |
|
MM-111 |
Merrimack |
HER2 x HER3 |
scFv |
HER2 Amplified Breast Cancer |
phase 2 |
|
SAR156597 |
Sanofi |
Il-4 x IL-13 |
DVD-Ig |
Pulmonaryfibrosis. |
phase 2 |
|
ABT-122 |
AbbVie |
TNF x IL-12 |
DVD-Ig |
RheumatoidArthritis |
phase 2 |
|
Blinatumomab |
Micromet |
C19 x CD3 |
BiTE |
Acute lymphoblasticleukemia |
Phase 3 |
|
